Edward J Gane

Summary

Country: New Zealand

Publications

  1. ncbi request reprint Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation
    Edward J Gane
    Auckland City Hospital, Auckland, New Zealand
    Gastroenterology 132:931-7. 2007
  2. doi request reprint Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
    Edward J Gane
    Auckland Clinical Studies, Auckland, New Zealand
    Lancet 376:1467-75. 2010
  3. ncbi request reprint Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand Electronic address
    Gastroenterology 146:736-743.e1. 2014
  4. doi request reprint Telbivudine improves renal function in patients with chronic hepatitis B
    Edward J Gane
    Auckland City Hospital, Auckland, New Zealand Electronic address
    Gastroenterology 146:138-146.e5. 2014
  5. doi request reprint Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Liver Transpl 19:268-74. 2013
  6. doi request reprint Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    N Engl J Med 368:34-44. 2013
  7. doi request reprint Future perspectives: towards interferon-free regimens for HCV
    Ed Gane
    New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand
    Antivir Ther 17:1201-10. 2012
  8. doi request reprint Future hepatitis C virus treatment: interferon-sparing combinations
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland, New Zealand
    Liver Int 31:62-7. 2011
  9. doi request reprint The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients
    Edward J Gane
    Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Int 30:1019-26. 2010
  10. doi request reprint Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
    Edward J Gane
    New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Int 31:676-84. 2011

Detail Information

Publications28

  1. ncbi request reprint Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation
    Edward J Gane
    Auckland City Hospital, Auckland, New Zealand
    Gastroenterology 132:931-7. 2007
    ..We report on long-term safety and efficacy of an alternative strategy of very low doses (400-800 IU/month) of intramuscular (IM) HBIG plus lamivudine...
  2. doi request reprint Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
    Edward J Gane
    Auckland Clinical Studies, Auckland, New Zealand
    Lancet 376:1467-75. 2010
    ....
  3. ncbi request reprint Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand Electronic address
    Gastroenterology 146:736-743.e1. 2014
    ....
  4. doi request reprint Telbivudine improves renal function in patients with chronic hepatitis B
    Edward J Gane
    Auckland City Hospital, Auckland, New Zealand Electronic address
    Gastroenterology 146:138-146.e5. 2014
    ..We analyzed changes in renal function using different markers of glomerular filtration rate (GFR) in multiple studies of telbivudine treatment of patients with chronic hepatitis B virus infection...
  5. doi request reprint Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Liver Transpl 19:268-74. 2013
    ..In conclusion, a combination of LAM and ADV initiated at the time of wait listing provides safe and effective protection against recurrent HBV infection without the high costs and inconvenience associated with long-term HBIG therapy...
  6. doi request reprint Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    N Engl J Med 368:34-44. 2013
    ..We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection...
  7. doi request reprint Future perspectives: towards interferon-free regimens for HCV
    Ed Gane
    New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand
    Antivir Ther 17:1201-10. 2012
    ..The likely duration of IFN-free direct-acting antiviral therapy will be between 6 and 12 weeks depending on early-on-treatment virological responses...
  8. doi request reprint Future hepatitis C virus treatment: interferon-sparing combinations
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland, New Zealand
    Liver Int 31:62-7. 2011
    ..It will also be important to minimise the emergence of multi-resistance, which would jeopardise future retreatment options...
  9. doi request reprint The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients
    Edward J Gane
    Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Int 30:1019-26. 2010
    ..The mitochondria-targeted anti-oxidant mitoquinone combines a potent anti-oxidant with a lipophilic cation that causes it to accumulate several-hundred fold within mitochondria in vivo...
  10. doi request reprint Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
    Edward J Gane
    New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Int 31:676-84. 2011
    ..Aims: To investigate the long-term efficacy and safety of telbivudine in the telbivudine-treated cohort from the GLOBE trial...
  11. pmc The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B
    Edward J Gane
    NZ Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    Hepatol Int 2:304-7. 2008
    ..In the future, improved on-treatment monitoring should facilitate treatment strategies to optimize long-term outcomes among patients receiving oral antiviral therapy for CHB...
  12. doi request reprint The natural history of recurrent hepatitis C and what influences this
    Edward J Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Transpl 14:S36-44. 2008
    ....
  13. ncbi request reprint Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study
    Szelin Peng
    Department of Surgery, University of Auckland, Auckland, New Zealand
    Am J Clin Nutr 85:1257-66. 2007
    ..Data describing the nutritional status of patients with liver cirrhosis of diverse origin, as assessed by direct body-composition methods, are limited...
  14. doi request reprint Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial
    Lindsay D Plank
    Department of Surgery, University of Auckland, Auckland, New Zealand
    Hepatology 48:557-66. 2008
    ..For the daytime group, no significant changes in TBP were seen. Daily energy and protein intakes at 3 months were higher than at baseline in both groups (P < 0.0001), and these changes did not differ between the groups...
  15. doi request reprint Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients
    Edward J Gane
    Auckland Clinical Studies, New Zealand
    J Hepatol 55:972-9. 2011
    ....
  16. doi request reprint Selection pressure on the hepatitis B virus pre-S/S and P open reading frames in Tongan subjects with a chronic hepatitis B virus infection
    William G H Abbott
    The New Zealand Liver Transplant Unit, Auckland City Hospital, Private Bag 92 024, Auckland, New Zealand
    Antiviral Res 96:148-57. 2012
    ..In conclusion, we could not find HLA class I-restricted selection pressure on any pre-S/S or P ORF amino acid; raising the possibility that peptide-based immunotherapies for chronic hepatitis B may not require peptides from these ORFs...
  17. ncbi request reprint Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis
    Sachin Mathur
    Department of Surgery, University of Auckland, Auckland, New Zealand
    J Gastroenterol Hepatol 23:239-43. 2008
    ..This study examines the independent prognostic significance of MELD, serum sodium and hydration status on long-term survival in patients with cirrhosis...
  18. doi request reprint Evidence for reduced selection pressure on the hepatitis B virus core gene in hepatitis B e antigen-negative chronic hepatitis B
    Brook G Warner
    Bioinformatics Institute, University of Auckland, Auckland, New Zealand
    J Gen Virol 92:1800-8. 2011
    ..There is a subtle relaxation in selection pressure on the HBV core gene in e-CHB. This may be due to impaired antiviral immunity, and could contribute to the high levels of viral replication that cause liver inflammation in this disease...
  19. ncbi request reprint Hypermetabolism predicts reduced transplant-free survival independent of MELD and Child-Pugh scores in liver cirrhosis
    Sachin Mathur
    Department of Surgery, University of Auckland, Auckland, New Zealand
    Nutrition 23:398-403. 2007
    ..The effect of hypermetabolism on prognosis in patients with cirrhosis has not been elucidated...
  20. pmc Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans
    William G H Abbott
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland 1023, New Zealand
    J Virol 84:621-9. 2010
    ..This assay may be useful for identifying the clinically significant HBV peptides that bind to common HLA class I molecules...
  21. doi request reprint Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders
    Edward J Gane
    Auckland Clinical Studies, Auckland, New Zealand
    Antimicrob Agents Chemother 58:1136-45. 2014
    ..DNVr plus peginterferon alfa-2a-ribavirin demonstrated high SVR24 rates in HCV G1b-infected prior null responders and was well tolerated. (This study has been registered at ClinicalTrials.gov under registration no. NCT01185860.). ..
  22. doi request reprint Oral β-blockade in relation to energy expenditure in clinically stable patients with liver cirrhosis: a double-blind randomized cross-over trial
    Wai Gin Lee
    Department of Surgery, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Metabolism 61:1547-53. 2012
    ..A larger, longer-term study with different eligibility criteria is required to investigate whether this treatment offers benefits additional to its use for prevention of variceal hemorrhage...
  23. doi request reprint Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool
    Helen L Pilmore
    Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand
    Transplantation 94:205-10. 2012
    ..Hence, we believe that strategies allowing transplantation of kidneys from donors with HBV can be undertaken safely with careful selection and matching of donors and recipients increasing access to kidney transplantation...
  24. ncbi request reprint Pre- and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy
    Lindsay D Plank
    University Department of Surgery, Auckland Hospital, Fifth Floor, Private Bag 92024, Park Road, Auckland 3, New Zealand
    Clin Nutr 24:288-96. 2005
    ..The goal of this study was to assess the safety of an immune-enhancing diet in patients undergoing liver transplantation and to investigate its effects on nutritional status...
  25. doi request reprint Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation
    Anna J Dare
    Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Liver Transpl 20:281-90. 2014
    ..In conclusion, BMI is an adequate tool for assessing obesity-associated risk in LT. Early post-LT morbidity is highest for patients with concomitant obesity and DM, although these factors do not appear to influence recipient survival...
  26. ncbi request reprint Genetic diversity and linkage disequilibrium in the Polynesian population of Niue Island
    William G H Abbott
    New Zealand Liver Transplant Unit, Auckland Hospital, Private Bag 92 024, Auckland, New Zealand
    Hum Biol 78:131-45. 2006
    ..High-powered linkage disequilibrium studies designed to map ancestral polymorphisms that influence complex genetic disease susceptibility may be feasible in this population...
  27. ncbi request reprint Hepatitis E in new zealand
    Harry R Dalton
    Gastroenterology Unit, Auckland City Hospital, Auckland, New Zealand
    J Gastroenterol Hepatol 22:1236-40. 2007
    ....
  28. ncbi request reprint Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 5:890-7. 2007
    ..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...